2016 Q3/Global Life Sciences
Rank | Chg | Organisation name | Overall |
|
---|---|---|---|---|
|
||||
1 | +7 |
Wockhardt
|
7.5 | |
|
||||
2 | +0 |
Neurocrine Biosciences
|
7.2 | |
|
||||
3 | +2 |
Yakult UK
|
7.1 | |
|
||||
4 | +17 |
Julphar
|
7.1 | |
|
||||
5 | +6 |
Kaken Pharmaceutical
|
7.1 | |
|
||||
6 | -2 |
Kyorin Holdings
|
6.9 | |
|
||||
7 | +76 |
Cytogen
|
6.8 | |
|
||||
8 | +10 |
Taisho Pharmaceutical
|
6.7 | |
|
||||
9 | +1 |
Mitsubishi Tanabe
|
6.7 | |
|
||||
10 | -7 |
Galenica AG
|
6.7 | |
|
||||
11 | +5 |
Meda Pharmaceuticals
|
6.7 | |
|
||||
12 | -3 |
MediGene
|
6.7 | |
|
||||
13 | +7 |
Anika Therapeutics
|
6.6 | |
|
||||
14 | +0 |
Abbott Uk
|
6.5 | |
|
||||
15 | -9 |
Biotecnol
|
6.5 | |
|
||||
16 | -1 |
Abbott
|
6.3 | |
|
||||
17 | +50 |
Lundbeck
|
6.3 | |
|
||||
18 | -1 |
Baxter International
|
6.1 | |
|
||||
19 | -7 |
Nissan Chemical
|
6.1 | |
|
||||
20 | +36 |
Genmab
|
6.1 | |
|
||||
21 | +50 |
Laboratoires Thea UK
|
6.1 | |
|
||||
22 | +2 |
Mitsubishi Tanabe Pharma Europe Ltd
|
6.1 | |
|
||||
23 | +19 |
Nippon Chemiphar
|
6.0 | |
|
||||
24 | -5 |
Actelion
|
6.0 | |
|
||||
25 | -18 |
Bavarian Nordic
|
6.0 | |
|
||||
26 | +7 |
CinnaGen
|
5.9 | |
|
||||
27 | +73 |
QLT
|
5.9 | |
|
||||
28 | +0 |
Debiopharm
|
5.9 | |
|
||||
29 | +2 |
EISAI UK
|
5.8 | |
|
||||
30 | -3 |
Pfizer UK
|
5.7 | |
|
||||
31 | -6 |
Merz
|
5.7 | |
|
||||
32 | -10 |
EISAI
|
5.6 | |
|
||||
33 | +4 |
Hospira
|
5.6 | |
|
||||
34 | +48 |
Ipsen UK
|
5.6 | |
|
||||
35 | +29 |
United Therapeutics
|
5.5 | |
|
||||
36 | -2 |
Dainippon Sumitomo
|
5.5 | |
|
||||
37 | -7 |
Forest
|
5.5 | |
|
||||
38 | +16 |
Toray Industries
|
5.4 | |
|
||||
39 | +42 |
Gruenenthal
|
5.4 | |
|
||||
40 | +3 |
Agennix
|
5.2 | |
|
||||
41 | +7 |
Stallergenes UK
|
5.2 | |
|
||||
42 | +7 |
Cipla
|
5.2 | |
|
||||
43 | -11 |
Mochida
|
5.2 | |
|
||||
44 | +6 |
Vitrolife
|
5.1 | |
|
||||
45 | +33 |
Boehringer Ingelheim
|
5.1 | |
|
||||
46 | -10 |
Covence
|
5.1 | |
|
||||
47 | -9 |
Genzyme UK
|
5.1 | |
|
||||
48 | +7 |
Galderma
|
5.0 | |
|
||||
49 | +8 |
Apotex
|
5.0 | |
|
||||
50 | -10 |
Asahi Kasei
|
5.0 | |
|
Changes in rank are compared to 2016 Q2/Global Life Sciences. Since then, 3 sites entered the survey and 49 sites could not be included in the rankings (1 more since last time). Build your own. Report statistics.
Priorities Summary
The priorities for this organization are not currently available to view.
Contact Us